Preventive and unlimited Corrective Repair (Essentialcare or equal) service agreement for a Surface Plasmon Resonance (SPR) Biacore T200 instrument, Base plus two (2) option years

The Food and Drug Administration Office of Acquisition and Grant Services is conducting a sources sought market survey for a preventive and unlimited corrective repair service agreement for a Surface Plasmon Resonance Biacore T200 instrument, with responses due by July 17, 2026. This is a market survey only; no contract award, cost reimbursement, or solicitation is forthcoming at this time.

The anticipated period of performance is a base year (August 30, 2026 through August 29, 2027) plus two optional one-year extensions. Work is performed on-site at FDA's Center for Biologics Evaluation and Research Federal Research Center, 10903 New Hampshire Avenue, Building 52/72, Silver Spring, Maryland. The NAICS classification is 811210 (Electronic and Precision Equipment Repair and Maintenance) with a small business size standard of $34 million; large businesses are also encouraged to respond.

Minimum performance requirements include one scheduled preventive maintenance visit per contract year during business hours using manufacturer-validated software and critical component exchange; unlimited on-site corrective maintenance and emergency repairs with all costs (engineer labor, travel, OEM-certified parts) included in the service agreement with no separate charges; priority technical support with an eight-hour remote response window and on-site Field Service Engineer dispatch within three business days if remote resolution fails within two business days; unlimited priority access to OEM online support, training modules, and hardware and software updates; and detailed field service reports after each visit using OEM-certified parts to OEM specifications.

Respondents must submit company information, business size status, SAM Unique Entity ID, descriptive literature, three years of past performance data, technical capability statements, response-time capabilities, GSA Schedule and BIC contract information if applicable, subcontracting opportunities for large businesses, warranty and payment terms, and pricing to suzanne.martella@fda.hhs.gov by 3:00 PM Central Time on July 17, 2026, referencing 75F40126SSN135706.